Meeting
2013 ASCO Annual Meeting
Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC).
Authors
Andrea P. Myers
Dana-Farber Cancer Institute, Boston, MA
Andrea P. Myers , Russell Broaddus , Vicky Makker , Panagiotis A. Konstantinopoulos , Ronny Drapkin , Neil S. Horowitz , Joyce Liu , Paul Van Hummelen , Funda Meric-Bernstam , Michael J. Birrer , L. Austin Doyle , Robert L. Coleman , Carol Aghajanian , Gordon B. Mills , Lewis Cantley , Ursula A Matulonis , Shannon Neville Westin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01307631
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5524)
DOI
10.1200/jco.2013.31.15_suppl.5524
Abstract #
5524
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer.
First Author: Panagiotis Konstantinopoulos
Poster
2017 ASCO Annual Meeting
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.
First Author: Neesha C. Dhani
Poster
2015 ASCO Annual Meeting
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
First Author: Andrea P. Myers
Poster
2014 ASCO Annual Meeting
Advanced or recurrent endometrial cancer (EC) and co-occurring mutations in multiple oncogenic pathways.
First Author: Alexandra Leary